Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

NCT04580485 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04580485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04580485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
February 3, 2021
Completion date
January 22, 2024
Enrollment
54 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, castration resistant prostate cancer, colorectal cancer, gastric/ gastroesophageal junction, hepatocellular carcinoma, non small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, squamous carcinoma of the anal canal, squamous cell carcinoma of head and neck, triple negative breast cancer